Clinical AI

Every answer.
Fully sourced.

Meddy's AI surfaces what the literature says about your patient's specific situation — with citations, not conclusions. You decide.

80M+
Peer-reviewed papers
1,400+
Clinical guidelines
140K+
Drug labels & monographs
01The Knowledge Base

Built on the sources
you already trust.

Meddy's AI is trained on drug labels, clinical practice guidelines, and over 80 million peer-reviewed academic papers. When it surfaces a recommendation, you can see exactly where it came from.

PubMed & MEDLINEADA Standards of CareFDA Drug LabelsACC / AHA GuidelinesCochrane ReviewsNEJM · JAMA · Lancet
Clinical Knowledge BaseUpdated continuously
Peer-Reviewed PapersPubMed · MEDLINE · Cochrane
80M+
92%
JAMAGLP-1 receptor agonist titration and A1c response in T2DM cohorts2024
Clinical Practice GuidelinesADA · ACC · AHA · USPSTF · WHO
1,400+
62%
ADAStandards of Medical Care in Diabetes — Section 9: Pharmacologic Approaches2025
Drug Labels & MonographsFDA · EMA · Health Canada
140K+
38%
FDAOzempic (semaglutide) — Prescribing Information, dosing & contraindications2024
Total indexed sources80,141,400+ and growing
02How It Works

Your patient's history.
The full literature.
One view.

Meddy takes everything it knows about the patient in front of you and cross-references against the evidence base to surface what's most relevant to their specific case.

This Patient
Marcus Reynolds · T2DM, HTN, Heart Failure
A1c worseningSemaglutide started Jan 4Sleep adherence ↓5-year history
The Evidence Base
80M+ papers · 1,400+ guidelines · 140K+ labels
JAMAADA Standards of CareFDA LabelsCochrane Reviews
Cross-Referenced
What does the literature say about a patient exactly like this one?
Surfaced To You
Reassess GLP-1 titration — cited, specific to Marcus, not a generic protocol
Not a chatbotNot a search engineA clinical knowledge layer that knows your patient
MRMarcus ReynoldsT2DM · Semaglutide started Jan 4
3 sources cited
Clinical Context
A1c worsening↑ 1.1% post-initiationGLP-1 · 0.5mg weeklySleep adherence ↓
AI Recommendation
Consider reassessing GLP-1 titration schedule given A1c rise post-initiation. Slower titration is associated with improved tolerability and glycemic response in comparable cohorts. Sleep disruption may be compounding glycemic instability — address concurrently.
Sources · 3 cited
1GLP-1 titration outcomes in T2DM — dose-response cohortJAMA Internal Medicine · 2023 · Vol 183 (4)
Dose-escalation rates for GLP-1 receptor agonists and glycemic response trajectories in adults with T2DM: a retrospective cohort analysisJAMA2023
Abstract excerpt

Among 4,812 adults initiating semaglutide, slower dose escalation over 12 weeks was associated with a 0.6% greater reduction in A1c at 6 months compared with standard titration (p<0.001), with significantly lower rates of GI-related discontinuation (8.1% vs 21.4%).

Why it's cited hereSupports slower titration for patients showing A1c rise in first 30 days of GLP-1 initiation.
DOI: 10.1001/jamainternmed.2023.0421
2Standards of Medical Care in Diabetes — Section 9ADA Standards of Care · 2025 · Pharmacologic Approaches
3Sleep disruption and glycemic variability in T2DM patientsDiabetes Care · 2024 · Vol 47 (2)
No recommendation without a source3 / 3 sources verified
03Access the Reference

No unsupported
suggestions. Ever.

Every recommendation the AI surfaces includes its source — the paper, the guideline, the drug label it drew from. You can read the evidence yourself before acting on anything.

You're not trusting the AI.
You're reading what it reads.
Every source is namedJournal, volume, year, DOI — always visible alongside the recommendation.
The excerpt is surfaced for youThe relevant passage from the abstract — why it was cited, in context — is shown inline.
Read the full paper in one clickLink out to the primary source whenever you want to go deeper.
04Physician Led

It assists.
You decide.

Meddy's AI is a tool in your hands — not a replacement for clinical judgment. It surfaces options, flags considerations, and grounds decisions in evidence. The call is always yours.

The AI does
Surfaces relevant literature
Flags drug interactions
Cites every source it uses
Identifies pattern changes
You do
Weigh the evidence
Know your patient
Make the clinical call
Override anything, always
AI Output
Physician Decision
Surfaces
Consider slower GLP-1 titration — supported by 3 sources
Strong evidence · JAMA 2023
Physician reviews
Patient motivated, tolerating well — explore before changing
Flags
Sleep disruption correlated with glycemic variability over same window
Diabetes Care · 2024
Physician adds context
Patient started new job — discussed stress management, sleep hygiene
Physician context added
Options surfaced
Metformin dose increase · CGM referral · Nutrition consult
ADA Standards 2025
Physician selects
CGM referral ordered. Nutrition consult scheduled. Hold Metformin change.
2 of 3 options acted on
Final authorityThe AI cannot act. It can only inform.Physician
Clinical AI

See it working on
a real case.

30 minutes with a Meddy physician advisor.

30 minutes
With a physician advisor
Live on a real patient case

No sales deck. No slides. Just the product, on a real case.